Biohaven Ltd. (NYSE:BHVN) Shares Purchased by FSC Wealth Advisors LLC

FSC Wealth Advisors LLC raised its position in shares of Biohaven Ltd. (NYSE:BHVN) by 3.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 15,500 shares of the company’s stock after buying an additional 500 shares during the period. FSC Wealth Advisors LLC’s holdings in Biohaven were worth $579,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. SpiderRock Advisors LLC acquired a new stake in Biohaven during the third quarter valued at approximately $620,000. Citigroup Inc. lifted its position in shares of Biohaven by 125.8% during the 3rd quarter. Citigroup Inc. now owns 119,905 shares of the company’s stock valued at $5,992,000 after acquiring an additional 66,801 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Biohaven during the 3rd quarter worth $1,339,000. JPMorgan Chase & Co. grew its holdings in shares of Biohaven by 85.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after acquiring an additional 372,737 shares during the last quarter. Finally, XTX Topco Ltd raised its position in shares of Biohaven by 278.5% during the third quarter. XTX Topco Ltd now owns 32,510 shares of the company’s stock worth $1,625,000 after purchasing an additional 23,921 shares during the period. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BHVN shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price target (up previously from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. TD Cowen boosted their price target on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. raised their price objective on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $59.00 target price on shares of Biohaven in a research note on Tuesday, December 17th. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $63.00.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs bought 29,000 shares of the stock in a transaction on Monday, December 30th. The shares were purchased at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the transaction, the director now directly owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. This represents a 1.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 16.00% of the stock is currently owned by company insiders.

Biohaven Price Performance

Shares of NYSE BHVN opened at $39.89 on Tuesday. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21. The business’s 50-day moving average price is $40.26 and its two-hundred day moving average price is $42.55. The company has a market capitalization of $4.03 billion, a P/E ratio of -4.27 and a beta of 1.29.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, equities analysts anticipate that Biohaven Ltd. will post -8.85 EPS for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.